Précis: Whole-genome sequencing of an outlier responder identified a tumorspecific synthetic lethal relationship between RAD50 mutation, checkpoint inhibition, and genotoxic chemotherapy. Précis: Longitudinal analysis of MCL tumors identified the relapse-specific BTK C481S mutation and provided evidence that targeting CDK4 overcomes ibrutinib resistance.
Précis: Longitudinal analysis of MCL tumors identified the relapse-specific BTK C481S mutation and provided evidence that targeting CDK4 overcomes ibrutinib resistance. Using whole-genome sequencing, Al-Ahmadie, Iyer, Hohl, and colleagues identified a clonal hemizygous RAD50 L1237F mutation in an outlier patient with metastatic small-cell ureter cancer who achieved a complete and durable response to treatment with a checkpoint kinase 1 inhibitor and irinotecan. RAD50 L1237F was accompanied by LOH of the wild-type allele and mutated a highly conserved residue required for proper MRE11 complex function in DNA repair. RAD50 mutation impaired activation of ataxia telangiectasia mutated (ATM) signaling, leading to a synthetic lethal effect when checkpoint inhibition was combined with DNA-damaging chemotherapy. These findings highlight the utility of this approach to dissect tumor-specific dependencies and provide a rationale for combining checkpoint inhibitors with DNA-damaging chemotherapy in patients whose tumors harbor MRE11 complex mutations. For details, please see the article by Al-Ahmadie, Iyer, Hohl, and colleagues on page 1014. 
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